Local Control Following Stereotactic Body Radiation Therapy for Liver Oligometastases: Lessons from a Quarter Century
Publication date
2023-10
Authors
Mheid, Sara
Allen, Stefan
Ng, Sylvia S.W.
Hall, William A.
Sanford, Nina N.
Aguilera, Todd A.
Elamir, Ahmed M.
Bahij, Rana
Intven, Martijn Pw
Radhakrishna, Ganesh
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
cc_by
Abstract
The utilization of stereotactic body radiation therapy for the treatment of liver metastasis has been widely studied and has demonstrated favorable local control outcomes. However, several predictive factors play a crucial role in the efficacy of stereotactic body radiation therapy, such as the number and size (volume) of metastatic liver lesions, the primary tumor site (histology), molecular biomarkers (e.g., KRAS and TP53 mutation), the use of systemic therapy prior to SBRT, the radiation dose, and the use of advanced technology and organ motion management during SBRT. These prognostic factors need to be considered when clinical trials are designed to evaluate the efficacy of SBRT for liver metastases.
Keywords
liver, oligometastases, SBRT, Oncology
Citation
Mheid, S, Allen, S, Ng, S S W, Hall, W A, Sanford, N N, Aguilera, T A, Elamir, A M, Bahij, R, Intven, M P W, Radhakrishna, G, Mohamad, I, De Leon, J, Tan, H, Lewis, S, Gani, C, Stanecu, T, Dell’Acqua, V & Hosni, A 2023, 'Local Control Following Stereotactic Body Radiation Therapy for Liver Oligometastases : Lessons from a Quarter Century', Current Oncology, vol. 30, no. 10, pp. 9230-9243. https://doi.org/10.3390/curroncol30100667